Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for SGYP
4.34
-0.06 (-1.36%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.27 - 4.52
52 week 3.81 - 6.70
Open 4.36
Vol / Avg. 783,213.00/1.45M
Mkt cap 406.08M
P/E     -
Div/yield     -
EPS -0.74
Shares 93.57M
Beta -0.21
Inst. own 26%
May 9, 2014
Q1 2014 Synergy Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 17, 2014
Q4 2013 Synergy Pharmaceuticals Inc Earnings Release
Feb 25, 2014
Synergy Pharmaceuticals Inc at Citi Global Healthcare Conference
Feb 24, 2014
Synergy Pharmaceuticals Inc at Citi Global Healthcare Conference
Feb 13, 2014
Synergy Pharmaceuticals Inc at Leerink Swann Global Healthcare Conference
Feb 10, 2014
Synergy Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -99.14% -112.99%
Return on average equity -123.26% -154.96%
Employees 25 -
CDP Score - -

Address

SUITE 2012, 420 LEXINGTON AVENUE
NEW YORK, NY 10170
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.

Officers and directors

Gabriele M. Cerrone Chairman of the Board
Age: 41
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 66
Bio & Compensation  - Reuters
Marino Garcia Senior Vice President - Corporate Development
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 65
Bio & Compensation  - Reuters
Alan F. Joslyn Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Christopher McGuigan Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Melvin K. Spigelman M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters